Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 4603Pancreatic Neoplasms 2843Carcinoma, Hepatocellular 2479Stomach Neoplasms 2329Colonic Neoplasms 1790Rectal Neoplasms 1719Esophageal Neoplasms 1376Liver Neoplasms 920Neoplasms 915Breast Neoplasms 839Neoplasm Metastasis 764Carcinoma, Non-Small-Cell Lung 705Cholangiocarcinoma 587Lung Neoplasms 556Ovarian Neoplasms 535Esophageal Squamous Cell Carcinoma 513Gastrointestinal Neoplasms 495Melanoma 381Prostatic Neoplasms 373Biliary Tract Neoplasms 373Head and Neck Neoplasms 303Uterine Cervical Neoplasms 288Carcinoma, Renal Cell 284Adenocarcinoma Of Esophagus 273Squamous Cell Carcinoma of Head and Neck 264Sarcoma 263Gastrointestinal Stromal Tumors 252Endometrial Neoplasms 235Urinary Bladder Neoplasms 226Gallbladder Neoplasms 225

Interventions

trifluridine tipiracil drug combination 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × First-line Treatment × Gastrointestinal × Clear all
NCT05221775 2022-02-03

Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

Tianjin Medical University Cancer Institute and Hospital

Phase 1 Unknown
18 enrolled
Gastrointestinal

First-line Treatment

NCT05077839 2021-10-25

TOBACO

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
184 enrolled
Gastrointestinal

First-line Treatment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡